July 2020

# I-MAB Presentation

# Disclaimer

This presentation has been prepared by I-Mab (the "Company") solely for information purpose. By viewing or accessing the information contained in this material, you hereby acknowledge and agree that no representations, warranties, or undertakings, express or implied, are made by the Company or any of its directors, shareholders, employees, agents, affiliates, advisors, or representatives as to, and no reliance should be placed upon, the accuracy, fairness, completeness, or correctness of the information or opinions presented or contained in this presentation. None of the Company or any of its directors, shareholders, employees, agents, affiliates, advisors, or representatives accept any responsibility whatsoever (in negligence or otherwise) for any loss howsoever arising from any information presented or contained in this presentation or otherwise arising in connection with the presentation. The information presented or contained in this presentation is subject to change without notice and its accuracy is not guaranteed.

This presentation does not constitute an offer to sell or issue or an invitation or recommendation to purchase or subscribe for any securities of the Company for sale in the United States or anywhere else. No securities of the Company may be sold in the United States without registration with the United States Securities and Exchange Commission (the "SEC") or an exemption from such registration pursuant to the Securities Act of 1933, as amended (the "Securities Act") and the rules and regulations thereunder. No part of this presentation shall form the basis of or be relied upon in connection with any contract or investment decision in relation to any securities or otherwise. This presentation does not contain all relevant information relating to the Company or its securities, particularly with respect to the risks and special considerations involved with an investment in the securities of the Company. Nothing contained in this presentation shall be relied upon as a promise or representation as to the past or future performance of the Company. Past performance does not guarantee or predict future performance. You acknowledge that any assessment of the Company that may be made by you will be independent of this presentation and that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company.

Certain statements in this presentation, and other statements that the Company may make, are forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. These statements reflect the Company's intent, beliefs, or current expectations about the future. These statements can be recognized by the use of words such as "expects," "plans," "will," "estimates," "projects," "intends," "anticipates," "believes," "confident," or words of similar meaning. These forward-looking statements are not guarantees of future performance and are based on a number of assumptions about the Company's operations and other factors, many of which are beyond the Company's control, and accordingly, actual results may differ materially from these forward-looking statements. The Company or any of its affiliates, advisers, or representatives has no obligation and does not undertake to revise forward-looking statements to reflect future events or circumstances.

THE INFORMATION CONTAINED HEREIN IS HIGHLY CONFIDENTIAL AND IS BEING GIVEN SOLELY FOR YOUR INFORMATION AND ONLY FOR YOUR USE IN CONNECTION WITH THIS PRESENTATION. THE INFORMATION CONTAINED HEREIN MAY NOT BE COPIED, REPRODUCED, REDISTRIBUTED, OR OTHERWISE DISCLOSED, IN WHOLE OR IN PART, TO ANY OTHER PERSON IN ANY MANNER. Any forwarding, distribution, or reproduction of this presentation in whole or in part is unauthorized.

By viewing, accessing, or participating in this presentation, you hereby acknowledge and agree to keep the contents of this presentation and these materials confidential. You agree not to remove these materials, or any materials provided in connection herewith, from the conference room where such documents are provided. You agree further not to photograph, copy, or otherwise reproduce this presentation in any form or pass on this presentation to any other person for any purpose, during the presentation or while in the conference room. You must return this presentation and all other materials provided in connection herewith to the Company upon completion of the presentation. By viewing, accessing, or participating in this presentation, you agree to be bound by the foregoing limitations. Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

# Key Investment Highlights

**Novel or Highly Differentiated**

Immuno-oncology and autoimmune disease

**Clinical Stage Company**

8 late-stage and early-stage assets

**Commercial Stage in 2 Years**

Expected product launch 2021 onwards

**$500m+ Raised Nasdaq listed**

From private rounds 2016-2019 and IPO 2020

*Founded as a discovery focused start-up in 2016*

*Moving towards a fully integrated global biopharma in 3-5 years*

# I-Mab Transitioning from I-Mab 1.0 to I-Mab 2.0




- Delivering clinical and corporate catalysts
- Building commercial capability/partnership
- Building manufacture capability
- Expanding global and regional partnerships

- Global portfolio of 12 assets
- China portfolio of 5 licensed clinical assets
- Raised US$ 500m from private rounds and IPO
- R&D capability and global footprint

# Innovative and Risk-Balanced Pipeline: *Two Portfolios*

China

**China Strategy – *Fast-to-Market***

**5** *clinical assets*

**BLA 2021 onwards**

Global → **In-licensing** → China

| Discovery | Pre-Clinical | IND Enabling | Phase 1 / Phase 2 | Phase 3 | BLA | Marketing |
|---|---|---|---|---|---|---|

China → US → **Global Partnership**

Global

**Global Strategy – *Fast-to-PoC***

**Internal R&D** **12** *clinical & pre-clinical assets*

**Clinical Validation**



# Innovative Pipeline of Novel and Highly Differentiated Potential

| | Drug Candidate (Licensor) | Current Indication & Therapeutic Area | Commercial Rights | Preclinical | Phase 1 | Phase 2 | Phase 3 or Registrational | Expected BLA in or before 2024 |
|---|---|---|---|---|---|---|---|---|
| China Portfolio | **Felzartamab TJ202 (MorphoSys)** [1]<br>*Differentiated CD38 antibody* | **Multiple myeloma**/ Autoimmune disease | Greater China | | | | 2L 3L | *BLA 2021*<br>*BLA 2023* |
| | **Eftansomatropin TJ101 (Genexine)** [2]<br>*Long-acting growth hormone* | **Pediatric growth hormone deficiency** | Greater China | | | | | *BLA 2023* |
| | **Olamkicept TJ301 (Ferring)**<br>*Soluble gp130 IL-6 inhibitor* | **Ulcerative colitis**/ Autoimmune disease | Greater China<br>S. Korea | | | | | |
| | **Enoblituzumab (MacroGenics)** [3]<br>*B7-H3 antibody* | **Head and neck cancer**/ Oncology | Greater China | | | | | |
| | **Efineptakin AlfaTJ107 (Genexine)**<br>*Novel long-acting IL-7* | **GBM**/ Oncology-related lymphopenia | Greater China | | | | | |
| Global Portfolio | **Plonmarlimab TJM2**<br>*GM-CSF antibody* | **CRS** and **RA**/ Autoimmune disease | Global | | | CRS | | *BLA (CRS)* |
| | **Lemzoparlimab TJC4**<br>*Differentiated CD47 antibody* | **AML, MDS**/ Oncology | Global | | | | | *BLA (AML)* |
| | **Ulilediimab TJD5**<br>*Differentiated CD73 antibody* | **Solid tumors**/ Oncology | Global | | | | | |
| | **TJ210 (MorphoSys)**<br>*Differentiated C5aR antibody* | **Solid tumors**/ Oncology, Autoimmune | Greater China<br>Global shared | | | | | |
| | **TJX7**<br>*Novel CXCL13 antibody* | **Sjogren's disease**/ Autoimmune disease | Global | | | | | |
| | **Bi-specific antibody panel** [4]<br>*including five PD-L1-based bi-specifics, TJ-C4GM and TJ-CLDN4B* | Oncology | Global<br>Some shared | | | | | |

**Notes**
1. TJ202 has two ongoing registrational trials, a monotherapy trial and a combination therapy trial in relapsed or refractory multiple myeloma in Greater China
2. For TJ101, we expect to submit an IND for a Phase 3 registrational trial in China in the first half of 2020
3. For enoblituzumab, we expect to initiate either a registrational trial or a Phase 2 trial (pending NMPA's regulatory approval) by the end of 2020
4. Our bi-specific antibody panel consists of (i) five PD-L1-based bi-specific antibodies, including TJ-L1I7 (PD-L1 and IL-7 cytokine fusion), TJ-L1C4 (PD-L1 and CD47), TJ-L1D5 (PD-L1 and CD73), TJ-L1H3 (PD-L1 and B7-H3), and TJ-L14B (PD-L1 and 4-1BB), (ii) TJ-C4GM (anti-CD47 and GM-CSF), and (iii) TJ CLDN4B (Claudin 18.2 and 4-1BB)

# The Emerging Value Drivers: *Critical Product Differentiation*

| Clinical Assets | Key Differentiation | Clinical Development Plan |
|---|---|---|
| **TJ202**<br>*Differentiated CD38 mAb* | **Short infusion time** (0.5 – 2 hrs) and **lower IRR** (7%)<br>Combination with **Lenalidomide** as 2nd line therapy | ▪ Two on-going registrational trials in **MM** to target **BLA in 2021**<br>▪ Ph 1b trial in **SLE** in 2020 |
| **TJ101**<br>*Differentiated long-acting hGH* | Convenient **weekly dosing** vs. daily injections<br>**Better safety profile** (HyFc) vs. pegylated hGH | ▪ Planned IND for **Ph 3 in PGHD** in mid 2020<br>▪ **BLA** expected in 2023 |
| **TJC4**<br>*Differentiated CD47 mAb* | **Strong anti-tumor activity**<br>**Minimal binding to RBC** due to a unique epitope<br>**No severe anemia** (GLP tox up to 100 mg/kg) | **US trial on-going in solid tumor/lymphoma:**<br>▪ Safety advantage (dose-escalation, 1-30 mg/kg)<br>▪ Combination with PD-1/CD20<br>**China trial starting:** AML/MDS |
| **TJD5**<br>*Differentiated CD73 mAb* | Intra-dimerization mechanism: **no "hook effect"**<br>MoA with **broader tumor indications** | ▪ **US trial on-going:** Phase 1 combo with PD-L1<br>▪ **China trial on-going:** Phase 1 combo with PD-1 |

# TJC4: Minimal Binding to Red Blood Cells by Design

## RBC Agglutination







## RBC Binding






# TJC4: Safety Advantage Demonstrated in Cyno Monkeys

## Pilot-single dose




## Pilot-repeat dose




## 4-wk GLP-Tox

**Male**




**Female**



# TJC4: Comparable Anti-Tumor Activity in Animal Models

Inject 1x10$^6$ Luci-Raji cells via tail vein in NSG mice

5 days

CD47 Abs treatment started 5 days post engraftment

i.p. injection q2d







**Treatment of TJC4 eradicated the engrafted tumor cells, comparable to 5F9 and 2A1 reference mAbs.**

# TJC4: Parallel Clinical Development in US and China

## US development goals:

- **Evaluation of the safety differentiation** in solid tumor/lymphoma to complete by Q3
- **Combination therapy** with PD-1 inhibitor pembrolizumab (KEYTRUDA®) and Rituximab (RITUXAN®) to evaluate safety and early efficacy signal in solid tumors and lymphoma

## China development goal:

- **AML/MDS.** Developing goal for registration in China for the indications



**TJC4** – ***A Differentiated CD47 Antibody in Clinical Development***



# TJD5: A Potential Highly Differentiated CD73 Antibody

## Highlights

TJD5

**Novel Mechanism Targeting Tumor Microenvironment**

**Differentiated CD73 Antibody Drug Candidate**




**TJD5's inhibition of CD73 by intra-dimerization**

## Advantages

**No "hook effect" through intra-dimerization mechanism**

**A substrate non-competitive pathway**

## Summary of Pre-clinical Results

Pre-clinical Data

Differentiated Property without the Hook Effect




Potentiation of Antitumor Activities in combination with PD-L1 Antibody




## Clinical Development Plan

**Targeting multiple solid tumor types, with parallel development in the U.S. and China**

Phase 1 clinical trial in patients with advanced solid tumors in partnership with TRACON Pharmaceuticals

- To evaluate safety & tolerability
- To explore PK/PD and potential efficacy of the combination therapy with atezolizumab

Phase 1/2 clinical trial in patients with advanced solid tumors including lung cancer, Obtained IND approval from the NMPA in September 2019

- To evaluate safety & tolerability
- To explore PK/PD and potential efficacy of the combination therapy with Toripalimab

# TJ202: Potential Best-in-Class CD38 Antibody for Multiple Myeloma and Autoimmune Diseases

## Highlights

### TJ202

| Differentiated CD38 mAb | First BLA Expected in 2021 | Potentials in Autoimmune Diseases |
|---|---|---|




**TJ202 binds to CD38 overexpressed tumor cells, pathogenic CD38-positive B cells and plasma cells, killing its mediator by inducing antibody-dependent cytotoxicity (ADCC) and antibody-dependent phagocytosis (ADCP)**

## Target Indication

### Multiple Myeloma (MM)

- Approximately **20,500** new cases of MM in 2018 in Greater China
- China MM biologics market size is estimated at US$ 0.8 billion in 2030
- Recently marketed daratumumab in China has a **long infusion time of administration (up to 6 hours)** and a **high infusion reaction rate (IRR)**

### Systemic Lupus Erythematosus (SLE)

- Estimated prevalence of 1.04 million in 2018 in Greater China
- China SLE biologics market size is estimated at **US$ 1.8 billion** in 2030
- Belimumab is currently the world's only biologic approved to treat SLE
- Unmet medical need for an efficacious and safe treatment alternative

## Advantages

### Convenience and Safety

**Shorter infusion time (0.5 – 2 Hours)**

**Lower infusion reaction rate (7%)**

### Expected Efficacy in Autoimmune Diseases

**Targeting pathogenic CD38-positive B cells and plasma cells**

# Eftansomatropin TJ101: Potential Best-in-Class Long-Acting Growth Hormone for Growth Hormone Deficiency

## Highlights

### TJ101

**Convenient Weekly or Bi-weekly Dosing with Safety Advantages**


**TJ101 is engineered using Genexine's proprietary hyFc technology**




**The clinical results from a Phase 2 trial in PGHD conducted in Europe indicated weekly or bi-weekly treatment with TJ101 produced similar efficacy compared to daily Genotropin administration**

## Target Indication

### Pediatric Growth Hormone Deficiency (PGHD)

- PGHD affected approximately **3.4 million** patients in 2018 in Greater China
- **Huge unmet medical need as only 3.7% of all PGHD patients** in China were receiving growth hormone replacement therapy in 2018
- China PGHD therapeutics market size is **US$ 0.6 billion in 2018**, and is estimated to increase to **US$ 3.2 billion in 2030**, a **CAGR of 15.7%**

**Short-Acting (Daily Injection)**

- Short-acting rhGH is the most commonly used treatment in China
- Not convenient with poor patient compliance

**Long-Acting (Weekly/Bi-weekly Injection)**

- Jintrolong is currently the only approved long-acting pegylated rhGH in China
- Potential safety concerns related to long-term use of pegylated drugs
- TJ101 is the only Fc-based long-acting rhGH ready for a Phase 3 clinical trial in China

## Clinical Development Plan

**Currently in preparation for a Phase 3, randomized, active controlled, and multi-center study to demonstrate non-inferiority of weekly TJ101 compared to Norditropin, a daily rhGH marketed in China**

**IND submitted in 2020**

# TJM2: Treatment for cytokine storm in severe COVID-19 infected patients

## Scientific rationale




GM-CSF and IL-6 are two key factors instigating cytokine storm in COVID-19. Antibodies neutralizing GM-CSF or IL-6/IL-6R may be used to prevent or treat cytokine storm associated with COVID-19.

## Advantages

- Specifically neutralizes GM-CSF which is key factor to induce cytokine storm in COVID-19
- Regulates the inflammatory cytokine network via the upstream intervention
- Targets myeloid lineage cells with no influence on lymphocytes to avoid the entire immune suppression
- Supported by preclinical research and safety profile of the phase 1 study

## GM-CSF blockade reduced cytokines that were elevated in COVID-19 patients




*Blood. 2019;133(7):697-709*
*Lancet. 2020 Jan 24. pii: S0140-6736(20)30183-5*

- Cytokines in **red** are elevated in severe COVID-19 cases requiring ICU.

## Clinical Development Plan

**Targeting severe COVID-19 patients in the U.S.**

I/E criteria:
- RT-PCR confirmed novel Coronavirus infection
- Imaging confirmed infection in both lungs
- Severe or critical novel Coronavirus pneumonia

Stratifications:
- Ventilation: yes/no
- Older than 60y: yes/no




**Primary endpoints:**
- Proportion of deterioration in clinical status from baseline (D14)

**Secondary endpoints:**
- SOFA score
- PaO2/FiO2
- Changes in serum cytokines
- All-cause mortality
- And etc.

# Expected Major Catalysts in 2020

| Category | 2020 | | |
|---|---|---|---|
| Clinical Milestone | **TJC4 US** safety data readout | **TJC4 China** trial start in AML/MDS | **TJ202 China** SLE trial start |
| | **TJD5 US** safety data readout | **TJD5 China** trial start in solid tumor | **TJ101 China** Ph 3 IND submission |
| | **TJM2 US** IND and Ph1b/2 trial for CRS | **TJM2 China** Ph 1b start in RA | **TJ301 China** Ph 2 topline data |
| | **TJ210 US** IND and Ph 1 trial start | | **TJ107 China** Ph 2 trial start |
| | **TJX7 US** IND and Ph 1 trial start | | |
| Corporate Milestone | | Expansion of US R&D center | Manufacture facility in China |
| | | | Potential global or China partnerships |

# Senior Management with a Proven Track Record of Success

## Zheru Zhang, Ph.D.

***President***

- 20+ years of experience in CMC and quality management in pharma industry in US, Korea and China
- Previously served management roles at BMS, J&J and Celltrion
- Led or participated in 20 biologics IND and six global BLA submissions
- Ph.D., University of Alberta
- M.S., Suzhou University



## Jielun Zhu, MBA, CFA

***CFO***

- 10+ years in investment banking, 4 years experience in healthcare consulting
- Served as MD and Asia Head of Healthcare Investment Banking for Jefferies, and a core healthcare team member at DB and UBS AG
- M.B.A., Harvard Business School
- B.A., Wesleyan University

## Joan Shen., M.D., Ph.D.

***CEO and Director***

- US licensed physician with 20+ years of clinical development experience and China
- Ex-China Clinical Head at Pfizer, Ex-CMO at Jiangsu Hengrui, Ex-China Development Head at J&J
- Ph.D., Postdoc, Indiana University School of Medicine
- M.S., West China University of Medical Sciences
- M.D., Southeast University Medical College

## Dr. Jingwu Zang, M.D., Ph.D.

***Founder, Honorary Chairman and Director***

- M.D., Shanghai Jiaotong University
- Ph.D., University of Brussels
- Post-doc, Harvard Medical School
- Clinical residency, Baylor College of Medicine, US-licensed physician

**Industry Experiences**

- 12 years of pharma R&D executives
- Ex-CSO and President of Simcere Pharmaceuticals
- Corporate SVP, Head of GSK China R&D Center

**Academic Achievements**

- Professor at Baylor College of Medicine
- Professor & founding director in Chinese Academy of Science
- Published over 160 papers in scientific journals

## Neil K. Warma, MBA

***US General Manager***

- Ex-President and Ex-CEO of Opexa Therapeutics (NASDAQ:OPXA), Ex-President and Ex-CEO of Viron Therapeutics, Founder and Ex-President of MedExact
- Ex-Head of International Pharma Policy & Advocacy at Novartis
- Board of Director of BioHouston
- B.Sc., University of Toronto
- M.B.A., Schulich School of Management at York University

# Distinguished Scientific Advisory Board

## Patricia LoRusso, D.O., M.A., Ph.D.

***Academic Achievements***
- Associate Director of Innovative Medicine and Director of Early Therapeutics Disease-Aligned Team at Yale Cancer Center

***Industry Experience***
- Member of the NCI Board of Scientific Council

***R&D Highlights***
- Dr. LoRusso heads the early clinical trials program at Yale Cancer Center and has been a Principal Investigator of the National Cancer Institute Phase 1/early phase clinical trials program grant in excess of 20 years

## Eric K. Rowinsky, M.D.

***Academic Achievements***
- Adjunct Professor of Medicine at New York University School of Medicine

***Industry Experience***
- Advisor to C-Bridge Capital
- U.S. Chief Medical Officer for Everest Medicines, Inc.

***R&D Highlights***
- At ImClone Systems (now a wholly-owned subsidiary of Eli Lilly), Dr. Rowinsky and his team developed and registered cetuximab (Erbitux) and ramucirumab in five indications and two other monoclonal antibodies

## Howard L. Weiner, M.D.

***Academic Achievements***
- Robert L. Kroc Professor of Neurology at the Harvard Medical School

***Industry Experience***
- Co-Director of the Ann Romney Center for Neurologic Diseases at Brigham & Women's Hospital in Boston

***R&D Highlights***
- Dr. Weiner pioneered immunotherapy in Multiple Sclerosis (MS) and has investigated immune mechanisms in nervous system diseases including MS, Alzheimer's disease, amyotrophic lateral sclerosis, stroke and brain tumors

## Yi-Long Wu, M.D.

***Academic Achievements***
- Winner of Outstanding Science Achievement from IASLC (IASLC Paul A. Bunn, Jr. MD Scientific Award)

***Industry Experience***
- Tenured Professor of Guangdong General Hospital (GGH)

***R&D Highlights***
- Prof. Wu is a pioneer of lung cancer research in China, gaining tremendous recognition from peers all over the world. He has committed himself to battling thoracic oncology at the front line

## Timothy A Yap, M.D, Ph.D.

***Academic Achievements***
- Associate Professor of Department for Investigational Cancer Therapeutics (Phase 1 Program) and the Department of Thoracic/Head and Neck Medical Oncology at the University of Texas MD Anderson Cancer Center

***Industry Experience***
- Medical Director of the Institute for Applied Cancer Science
- Associate Director of Translational Research in the Institute for Personalized Cancer Therapy

***R&D Highlights***
- Dr. Yap's main research focuses on the first-in-human and combinatorial development of molecularly targeted agents and immunotherapies, their acceleration through clinical studies using novel predictive and pharmacodynamics biomarkers

## Roy S. Herbst, M.D, Ph.D.

***Academic Achievements***
- Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology and the Chief of Medical Oncology at Yale Cancer Center and Smilow Cancer Hospital

***Industry Experience***
- Associate Cancer Center Director for Translational Research, Yale Cancer Center in New Haven

***R&D Highlights***
- Dr. Herbst is best known for his work in developmental therapeutics and the personalized therapy of non-small cell lung cancer, in particular the process of linking genetic abnormalities of cancer cells to novel therapies

# Dual Expertise in U.S. and China with Strategic Global Footprint of Partners


**Notes**

1. Headquarters of companies that partner with I-Mab.
2. In April 2017, our subsidiary I-Mab Shanghai entered into a technology transfer agreement (the "HDYM License") with Ningbo Hou De Yi Min Information Technology Co., Ltd. ("HDYM") and Hangzhou HealSun Biopharm Co., Ltd. ("HealSun"), which is a portfolio company of Lepu Biotech.
3. In March 2020, our subsidiary I-Mab Biopharma US Limited entered into a strategic alliance agreement with Kalbe Genexine Biologics, a joint venture between Kalbe Farma Tbk and Genexine, Inc.

# Strategic Partnerships with Leading Global Companies

## Multiple Collaborations Established with Quality Partners

| | Product | Partner | Partner Market Cap | Ticker | Commercial Rights | Date |
|---|---|---|---|---|---|---|
| **In-license** | Olamkicept (IL-6 blocker) | FERRING PHARMACEUTICALS | Private | Private | Greater China, S. Korea | 2016.11 |
| | TJ202 (CD38)<br>TJ210 (C5aR) | morphosys | US$ 3.4Bn | FRA: MOR,<br>NASDAQ: MOR | Greater China<br>Greater China, S. Korea | 2017.11/<br>2018.11 |
| | TJ101 (Long-acting hGH) /<br>Efineptakin TJ107 | Genexine | US$ 1.1Bn | KOSDAQ: 095700 | China<br>Greater China | 2015.10/<br>2017.12 |
| | Enoblituzumab (B7-H3 antibody) | MACROGENICS | US$ 549.6Mn | NASDAQ: MGNX | Greater China | 2019.07 |
| **Partnership** | WuXiBody Platform<br>Strategic Manufacturing Partner<br>Investor | WuXi Biologics Global Solution Provider | US$ 12.9Bn | SEHK: 2269 | Worldwide | 2018.09/<br>2019.04/<br>2019.07 |
| | Strategic Commercial Partner | KALBE | US$ 2.9Bn | IDX:KLBF | South East Asia, MENA | 2020.03 |
| **Co-development** | Tecentriq for combo with TJD5 | Roche | US$ 247.0Bn | SWX: ROG | Global (excl China) | 2019.03 |
| | KEYTRUDA® (pembrolizumab) for combo with TJC4 | MSD | US$ 216.8Bn | NYSE:MRK | Worldwide | 2019.09 |
| | Toripalimab (anti-PD-1 mAb) for combo with TJD5 | 君实生物 TopAlliance | US$ 2.8Bn | SEHK: 1877,<br>NEEQ: 833330 | China | 2019.09 |
| | TJD5 (CD73 antibody) | TRACON PHARMACEUTICALS | US$ 9.0Mn | NASDAQ: TCON | North America | 2018.11 |
| **Out-license** | PD-L1 antibody | LEPU MEDICAL | US$ 6.9Bn | SZSE: 300003 | Worldwide | 2017.04 |
| | Bispecific antibody | ablbio | US$ 734.9Mn | KOSDAQ: 298380 | Ex- Greater China | 2018.07 |
| | TJ103<br>long-acting GLP-1 | CSPC 石药集团 | US$ 13.3Bn | SEHK: 1093 | Greater China | 2018.12 |

# Strong Shareholder Base with Prominent Investors

**Raised over US$500 Million in 3 Years with Leading Chinese and Global Healthcare and Biotech Investors**



# Raised Over US $500 Million with Leading Global Healthcare and Biotech Investors

## Shareholder Breakdown (1)(3)




## Fundraising History

| Round | Amount ($USD) |
|---|---|
| Seed | $2.3M |
| Series A | $58M |
| Series B | $120M |
| Series C | $200M |
| Series C-1 | $27M |
| IPO | $115M |
| **TOTAL** | **$522.3M** |

Note:
1. Based on common shares outstanding
2. Other IPO shareholders exclude: GIC, Genexine, Lake Bleu, C-Bridges
3. ESOP on fully diluted basis is 13.4% of shares outstanding

(2)

# Well Capitalized to Pursue Ongoing R&D Activities

## Total Cash Position [1]




## Historical Revenue




## 2019 R&D Expenses

**2019 R&D expenses total RMB$840.4MM (US$120.7MM) which primarily consists of:**

- CRO service fees
- In-licensed patent right fees, including US$15mil upfront payment to MacroGenics
- Employment benefit expenses, including upfront R&D staff salary and benefits payment
- Material cost for drug candidates

Note:
1. Total cash position include: cash and cash equivalent, restricted cash, and short-term investments. Restricted cash represents cash that cannot be withdrawn without the permission of third parties, and deposits held in a separate reserve account as security deposits under bank borrowing agreements

# Financial Summary

| Selected Financials | Full Year Ended | |
|---|---|---|
| (All amounts in RMB thousands, except for per share data) | December 31, 2018 | December 31, 2019 |
| Cash, Cash Equivalents, Restricted Cash and Short-Term Investments | 1,680,931 | 1,225,283 |
| Total Revenues (Licensing and Collaboration Revenue) | 53,781 | 30,000 |
| Total Expenses | (492,419) | (1,494,968) |
| Research & Development Expenses | (426,028) | (840,415) |
| Administrative Expenses | (66,391) | (654,553) |
| Net Loss | (402,833) | (1,451,950) |
| Net Loss Attributable to Ordinary Shareholders | (402,833) | (1,485,001) |
| Net Loss Per Share Attributable to Ordinary Shareholders (Basic and Diluted) | (61.7) | (201.2) |
| Non-GAAP Adjusted Net Loss | (399,313) | (936,747) |
| Non-GAAP Adjusted Net Loss Attributable to Ordinary Shareholders | (399,313) | (969,798) |
| Non-GAAP Adjusted Net Loss Per Share Attributable to Ordinary Shareholders (Basic and Diluted) | (61.2) | (131.4) |